Introduction
============

Maintaining protein homeostasis is essential for normal cellular function and viability. This is overseen by PQC mechanisms, through the control of protein synthesis, localization, folding/refolding, degradation and formation of protein inclusions. At the post-translational level, PQC is orchestrated by several mechanisms including chaperones that maintain correct protein conformation or help refold misfolded proteins; and the UPS and ALP, which degrade proteins that are irreversibly misfolded, damaged, or are no longer required by the cell. In this review, we focus on these aspects of PQC; with other PQC pathways reviewed elsewhere ([@B149]; [@B39]). In eukaryotes, protein chaperones are essential for ensuring the correct folding of nascent proteins and refolding of misfolded proteins. Hsps or heat shock chaperones (Hscs) are a prominent group of chaperones and they can be found in the ER, mitochondria, cytoplasm or extracellular space ([@B54]; [@B150]). Protein degradation through the UPS is regulated by the sequential activity of E1, E2, and E3 enzymes that conjugate primarily K48-linked ubiquitin (Ub) chains onto lysine residues in proteins destined for elimination through the 26S proteasome ([@B104]). The ALP acts mainly through macroautophagy and CMA. In macroautophagy, cytoplasmic content (including soluble and aggregated proteins) is engulfed by a double-membrane to form an autophagosome that fuses with the lysosome forming an autolysosome, degrading the autophagosomal content ([@B12]). In CMA, Hsc70 specifically binds to and targets proteins containing KFERQ-like motifs to the lysosomal receptor Lamp2A for client import through the lysosomal membrane, and subsequent degradation by lysosomal hydrolases ([@B27]). In addition, chaperones and ubiquitination systems promote the spatial sequestration of misfolded proteins into inclusions (aggresome/Q-bodies) and mediate the lysosomal degradation of toxic aggregates through the aggresome--autophagy and multivesicular body pathways ([@B62]; [@B116]; [@B42]; [@B130]). These pathways are regulated by K63-linked Ub chains and are critical for the degradation of aggregated proteins including α-synuclein (α-syn) ([@B135]; [@B44]; [@B142]). Inefficient PQC is implicated in protein toxicity, gain- or loss-of-function in many pathologies, including several neurodegenerative diseases known as synucleinopathies. Synucleinopathies, which include PD, LBD and MSA, are characterized by the pathologic accumulation and aggregation of α-syn ([@B83]). As some mutations altering PQC machinery are associated with familial forms of synucleinopathies and α-syn pathologic aggregates impair PQC, targeting the PQC machinery has become a promising therapeutic strategy for opposing the toxic effects of misfolded α-syn aggregates (**Figure [1](#F1){ref-type="fig"}**).

![Principal PQC mechanisms involved in α-syn homeostasis and potential therapeutic approaches. In physiologic conditions, misfolded α-syn protein is degraded by PQC machinery: the UPS is responsible for ubiquitination of α-syn leading to proteasomal degradation of α-syn, while macroautophagy and CMA both lead to lysosomal degradation of misfolded α-syn. In synucleinopathies, alterations in these protective mechanisms result in the accumulation of misfolded α-syn in aggregates and Lewy bodies (LB) that lead to neuronal dysfunction and death. Genetic or pharmaceutical approaches to restore altered PQC pathways or stimulate alternative PQC pathways: (1) Inhibition of α-syn expression could prevent its pathological accumulation. (2) Overexpression of Lamp2A lysosomal receptor could increase the CMA of misfolded α-syn. (3) Pharmaceutical inhibition of mTOR, an autophagy receptor, stimulates macroautophagy preventing α-syn accumulation and aggregation. (4) Overexpression of the transcription factor NRF2 activates both macroautophagy and CMA and stimulates the lysosomal degradation of misfolded α-syn. (5) Improving lysosomal hydrolases activity or (6) stimulating lysosomal biogenesis could also enhance α-syn lysosomal degradation. α-syn aggregation can also be prevented by stimulation or overexpression of (7) endogenous or (8) secretory chaperones.](fnmol-10-00311-g001){#F1}

Misfolding and Spreading of α-syn in Synucleinopathies
======================================================

α-syn, a 140-amino acid protein encoded by the *SNCA* gene, is abundant in the human brain (1% of all cytosolic proteins) ([@B133]) and is implicated in various cellular processes including vesicular trafficking, dopamine release and reuptake ([@B1]; [@B121]; [@B34]; [@B16]). α-syn is structured into three domains: the N-terminal amphipathic domain, which allows membrane-binding; the central hydrophobic non-amyloid-β component (NAC) domain, essential for α-syn aggregation; and the acidic, negatively charged C-terminal domain, that is critical for chaperone-like activity during thermal and chemical stress ([@B131]; [@B2]; [@B13]). Under physiological conditions, α-syn is soluble and intrinsically disordered, or can adopt an N-terminal α-helix conformation with high affinity for biological membranes ([@B8]). In synucleinopathies, α-syn follows sequential aggregation/fibrillization, starting from soluble monomers, dimers, and misfolded oligomers that aggregate into insoluble protofibrils and fibrils with an anti-parallel β-sheet structure ([@B33]; [@B111]; [@B112]).

Aggregation of α-syn leads to the formation of proteinaceous inclusions termed Lewy bodies (LB) and Lewy neurites ([@B148]). In PD, α-syn pathology has been shown to spread from brainstem to neocortex following a specific pattern ([@B14]). Recent evidence suggests that this is due to the prion-like, cell-to-cell propagation of α-syn aggregates ([@B81]; [@B51]). This concept was established in cells containing α-syn fibrils that secrete α-syn seeds taken up by surrounding healthy cells. In these recipient cells, exogenous protofibrils seed the aggregation of endogenous soluble α-syn monomers, causing α-syn to adopt an insoluble β-sheet conformation. This results in the formation of new α-syn seeds, which spread into neighboring cells ([@B147]; [@B76],[@B77]; [@B88]).

Targeting PQC Defects as Potential Neuroprotective Strategies Against α-syn Pathology
=====================================================================================

Chaperones
----------

The first indication that chaperones confers neuroprotection in α-syn--induced pathogenesis was Hsp70 overexpression protecting against α-syn toxicity in *Drosophila* ([@B6]). Accordingly, modulating chaperone function through chemical or genetic approaches holds great therapeutic promise for synucleinopathies. Chaperones ensure the correct folding of nascent and mature protein chains ([@B41]; [@B123]). They also prevent seeding of new aggregates and fibrillization by occluding surfaces that may serve as platforms to induce misfolding of native proteins ([@B54]). To some extent, Hsp110, Hsp70 and Hsp40 chaperones can disassemble α-syn fibrillary aggregates *in vitro* ([@B40]; [@B48]). Enhancing disaggregase activity genetically or with pharmacological modulators could counteract α-syn aggregation ([@B48]; [@B59]; [@B126]; [@B123]). Whether disaggregation occurs *in vivo* remains to be established, and since this process might generate soluble, potentially toxic forms of misfolded α-syn, simultaneous enhancement of α-syn degradation is likely necessary for beneficial effects.

Targeting Hsp70/Hsp90 signaling is of prime interest, not only in synucleinopathies, but also in other adult-onset proteinopathies ([@B106]). These chaperones have opposing effects: Hsp90 stabilizes its clients, whereas Hsp70 directs them for proteasomal degradation upon Hsp90 dissociation. In yeast, cellular, or animal models of PD, inhibiting Hsp90 activity ([@B5]; [@B7]; [@B107]) or stimulating Hsp70 activity ([@B6]; [@B85]; [@B66]; [@B158], [@B157]; [@B125]; [@B156]; [@B9]; [@B103]) and that of its collaborator Hsp40 ([@B85]; [@B43]) reduces α-syn oligomerization, inclusions formation, and toxicity, and diminishes α-syn levels (**Table [1](#T1){ref-type="table"}**). Although induction of chaperone expression in various cellular locations during proteotoxic stress and its associated stress response is observed in the brains of patients affected by synucleinopathies, α-syn aggregates still accumulate, indicating that the chaperone machinery is overwhelmed. This is supported by findings that many chaperones (including Hsp70, Hsp90 and Hsp40) or mediators of the heat-shock response (HDAC6) are found in LBs (**Table [1](#T1){ref-type="table"}**), possibly reflecting a cellular attempt to sequester soluble, harmful misfolded species of α-syn ([@B42]). Other chaperones can also mitigate α-syn aggregation and toxicity in various models (see **Table [1](#T1){ref-type="table"}**). Overall, it appears evident that modulation of chaperone function is an innovative therapeutic approach against α-syn toxicity. In a clinical context, where widespread α-syn aggregation has already occurred, a global increase in chaperoning activity such as stimulation of the heat-shock response ([@B38]) might have a greater impact than manipulation of individual chaperones. The use of pharmacological chaperones (e.g., flavonoids or polyphenols, [@B21]; [@B109]; [@B49]) to prevent or revert α-syn aggregation may also complement therapeutic modulation of endogenous chaperones.

###### 

Therapeutic avenues for targeting PQC pathways in the treatment of synucleinopathies.

  Target                             Physiological function                                                                                                                                                                       Implication in disease                                                                       Therapeutic strategies                                                                                                                                                                                                                                  Therapeutic effect                                                                                                                                                                                                                                                                                                                                                                                                                  Reference
  ---------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  **Chaperoning**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Hsp70 (*HSPA1A*)                   Directs client proteins for degradation by the UPS; serves as a disaggregase against fibrillary aggregates                                                                                   Component of Lewy bodies in PD                                                               Induction of expression by small molecules (e.g., geldanamycin)^10^; genetic overexpression^1,3,6,8^; induction by cell-penetrating recombinant DJ-1 protein^2^ (*PARK7*), by phenylbutyrate-induced DJ-1 expression^9^, or by CHIP overexpression^6^   Protects against α-syn toxicity in *Drosophila melanogaster* despite the presence of inclusions^1^; reduces insolubility of α-syn in α-syn overexpressing mice^3^; prevents α-syn accumulation and aggregation in human H4 neuroglioma cells^4,5^ and dopaminergic MES cells; in dopaminergic N27 cells, protects against α-syn toxicity^9^; in SK-N-SH cells^7^, prevents oxidative stress, dopamine (DA) loss and cell death^2^   [@B6]^1^, [@B7]^10^; [@B85]^4^; [@B66]^3^; [@B158]^8^, [@B157]^9^; [@B125]^6^; [@B156]^7^; [@B9]^2^; [@B103]^5^; [@B40]; [@B48]; [@B59]; [@B126]; [@B123]
  Hsp90 (*HSP90AB 1*)                Stabilizes client proteins by preventing Hsp70-mediated UPS targeting; favors fibrillization of α-syn, shifting the aggregation eqilibrium away from early toxic soluble misfolded species   Component of Lewy bodies in PD, increase in insoluble fraction in temporal cortex from LBD   Inhibition by small molecules (e.g., geldanamycin)^10^                                                                                                                                                                                                  Reduces α-syn aggregation and toxicity in human H4 cells^11^; protects against α-syn toxicity in *D. melanogaster* despite the presence of inclusions^10^                                                                                                                                                                                                                                                                           [@B5]; [@B7]; [@B19]^11^; [@B107]; [@B48]
  Hsp40 (*DNAJB1*)                   With Hsp70, targets client proteins for UPS-mediated degradation; participates in α-syn disaggregation together with Hsp110 and Hsp70                                                        Component of Lewy bodies in PD                                                               Overexpression by transfection^4,12^                                                                                                                                                                                                                    Reduces α-syn aggregation in human H4 cells^4^; lowers α-syn accumulation and aggregation in SK-N-SH cells^12^                                                                                                                                                                                                                                                                                                                      [@B85]^4^; [@B43]^12^; [@B40]; [@B59]; [@B126]; [@B123]
  Torsin-1A (*TOR1A*)                Chaperone with ATPase activity, homolog of yeast Hsp104                                                                                                                                      Component of Lewy bodies and Lewy neurites in LBD                                            Overexpression by transfection^12^                                                                                                                                                                                                                      Reduces α-syn aggregation in human H4 cells                                                                                                                                                                                                                                                                                                                                                                                         [@B85]
  proSAAS (*PCSK1N*)                 Neural-specific secretory chaperone, prevents α-syn aggregation                                                                                                                              Component of Lewy bodies in PD                                                               Overexpression using viral vector; extracellular treatment with recombinant proSAAS^13^                                                                                                                                                                 Blocks α-synuclein-induced cytotoxicity in primary cultures of nigral dopaminergic neurons and in dopaminergic SH-SY5Y cells^13^                                                                                                                                                                                                                                                                                                    [@B60]^13^
  ERdj5 (*DNAJC10*)                  Endoplasmic reticulum-resident thioredoxin disulfide reductase, regulates degradation of misfolded proteins via ERAD (endoplasmic-reticulum associated degradation)                          Unknown                                                                                      Overexpression in transgenic *C. elegans*^14^                                                                                                                                                                                                           Protects against α-syn aggregation and toxicity, restoring age-dependent mobility defects and loss of dopaminergic neurons in *Caenorhabditis elegans*^14^                                                                                                                                                                                                                                                                          [@B90]^14^
  GRP78 (*HSPA5*)                    Endoplasmic reticulum-resident chaperone, induced during the Unfolded Protein Response                                                                                                       Unknown                                                                                      Recombinant Adeno-Associated Viruses (rAAV)-mediated overexpression in the substantia nigra (SN)                                                                                                                                                        In rats overexpressing α-syn in the substantia nigra, co-overexpression of GRP78 attenuates α-syn-induced dopaminergic neuron loss and motor deficits^15^                                                                                                                                                                                                                                                                           [@B52]; [@B118]^15^
  TRAP-1 (*TRAP1*)                   Mitochondrial Hsp75 chaperone with ATPase activity                                                                                                                                           Unknown                                                                                      Overexpression^16^                                                                                                                                                                                                                                      Suppresses α-syn toxicity in mutant A53T α-syn expressing *D. melanogaster*, rat primary neurons and HEK293 cells^16^                                                                                                                                                                                                                                                                                                               [@B17]^16^
  HDAC6 (*HDAC6*)                    Histone deacetylase, mediates α-syn degradation by inducing the Heat Shock Response                                                                                                          Component of Lewy bodies in PD                                                               Overexpression by transfection^17^                                                                                                                                                                                                                      Decreases α-syn oligomers and toxicity in SK-N-SH cells^17^                                                                                                                                                                                                                                                                                                                                                                         [@B86]; [@B38]^17^
  **Ubiquitin-Proteasome System**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  UCHL1 (*UCHL1*)                    Ubiquitin carboxy-terminal hydrolase, involved in the processing of ubiquitin precursors and ubuquitinated proteins                                                                          Mutated in an autosomal-dominant form of PD, component of LB in sporadic PD                  Pharmacological inhibition using LDN-57444^18^                                                                                                                                                                                                          In primary neurons and hippocampal tissue of α-syn overexpressing mice, enhanced synaptic clearance of α-syn^18^                                                                                                                                                                                                                                                                                                                    [@B79]; [@B151]; [@B20]^18^; [@B69]
  CHIP (*STUB1*)                     E3 ubiquitin-protein ligase, targets toxic α-syn oligomers toward proteasome- and ALP-mediated degradation                                                                                   Component of Lewy bodies in PD                                                               Gene therapy (overexpression using a viral vector)^19^                                                                                                                                                                                                  Mediates the degradation of α-syn *in vivo* in rats, but also induces tyrosine hydroxylase degradation, limiting its therapeutic interest^19^                                                                                                                                                                                                                                                                                       [@B125]; [@B140]; [@B35]^19^
  USP9X (*USP9X*)                    Deubiquitinates α-syn, preventing its degradation by the proteasome                                                                                                                          Decreased activity in PD and LBD, component of LB                                            Overexpression by transfection^20^                                                                                                                                                                                                                      Decreases α-syn aggregation and toxicity in SH-SY5Y dopaminergic cells upon proteolytic impairment^20^                                                                                                                                                                                                                                                                                                                              [@B114]^20^
  **Macroautophagy**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  mTOR (*MTOR*)                      Serine/Threonine kinase which acts as an autophagy repressor                                                                                                                                 Decreased activity in patient-derived GBA mutant fibroblasts                                 Inhibition using rapamycin^21,22^                                                                                                                                                                                                                       Autophagic clearance of α-syn, protection of DA neurons and improvement in motor function in rodents^21,22^ (with possible adverse effects)                                                                                                                                                                                                                                                                                         [@B64]; [@B32]^21^; [@B78]; [@B141]^22^
  SIRT2 (*SIRT2*)                    Deacetylates α-syn on lysines 6 and 10                                                                                                                                                       Unknown                                                                                      Knock-out in mice^23^                                                                                                                                                                                                                                   In mice, protects against DA neurons loss caused by overexpression of α-syn in the SN, or by MPTP injection^23^                                                                                                                                                                                                                                                                                                                     [@B31]^23^
  PLK2 (*PLK2*)                      Phosphorylates α-syn at S129 to stimulate its removal by autophagy                                                                                                                           Upregulated in LBD- affected brains                                                          AAV-mediated overexpression in the SN^24^                                                                                                                                                                                                               Reduces α-syn accumulation, DA neurons loss and motor deficits in a rat genetic model of PD^24^                                                                                                                                                                                                                                                                                                                                     [@B82]; [@B102]^24^; [@B30]
  Beclin-1 (*BECN1*)                 Regulates the PI3K complex, stimulating autophagosome formation                                                                                                                              Unknown                                                                                      Overexpression (lentivirus)^25^                                                                                                                                                                                                                         Reduces α-syn accumulation, ALP defects and neuronal pathology in α-syn transgenic mice^25^                                                                                                                                                                                                                                                                                                                                         [@B132]^25^
  Spermidine                         Activates autophagy, counteracting age-assocaited cell death                                                                                                                                 Unknown                                                                                      Spermidine administration^26^                                                                                                                                                                                                                           Rescues α-syn toxicity, motor deficits and loss of DA neurons in *C. elegans* and *D. melanogaster^26^*                                                                                                                                                                                                                                                                                                                             [@B18]^26^
  **Chaperone-mediated autophagy**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Lamp2A (*LAMP2*)                   CMA receptor, rate-limiting factor of CMA. Translocates α-syn into lysosomes for degradation                                                                                                 Decreased levels correlate with α-syn accumulation in PD                                     Overexpression using AAV or rAAV^27^                                                                                                                                                                                                                    Upregulates CMA activity, reducing α-syn levels and α-syn toxicity in SH-SY5Y DA cells, rat primary cortical and nigral DA neurons^27^                                                                                                                                                                                                                                                                                              [@B152]^27^; [@B92]; [@B153]

Targets: main PQC pathways and biological targets with therapeutic potential. Physiologic function: function of the target with respect to α-syn--relevant biological pathways. Implication in disease: pathologic evidence for the implication of the target in patients with synucleinopathies. Therapeutic strategies: describes experimental strategies used to manipulate a given target. Therapeutic effect: describes biologic effects on α-syn pathology observed upon application of the corresponding therapeutic strategies. Superscript numbers indicate the corresponding references for each model. The corresponding human Gene Symbol related to proteins of interest is indicated in parentheses

.

Ubiquitin-Proteasome System
---------------------------

Dysfunction in the UPS contributes to α-syn pathology with proteasomal subunits and ubiquitinated α-syn observed in LBs ([@B58]; [@B55]). In sporadic PD, 20S and 26S proteasome activity are reduced, and α-syn aggregates can inhibit proteasome function ([@B10]; [@B136]). Many dysfunctions in Ub ligases (specifically E3s) have been linked to α-syn quality control. Indeed, various E3s have been identified in LBs, including CHIP (**Table [1](#T1){ref-type="table"}**), E6AP and SIAH ([@B120]; [@B74]; [@B125]; [@B89]). CHIP, a co-chaperone with E3 Ub ligase activity, regulates α-syn proteasomal degradation, in collaboration with Hsc70, Hsp70, and Hsp90. Like CHIP, E6AP triggers α-syn degradation while SIAH monoubiquitinates α-syn to promote its aggregation ([@B115]; [@B89]). Mutations in the gene encoding Parkin E3 Ub ligase are responsible for inherited PD ([@B97]; [@B75]). Although these loss-of-function mutations are associated with PD, they do not lead to LB pathology ([@B124]). It has been suggested that Parkin K63-linked polyubiquitination favors LB formation ([@B95]; [@B68]; [@B96]), and deficient Parkin activity would favor accumulation of earlier, potentially toxic aggregation intermediates. However, this awaits further confirmation, and to date, the role of Parkin Ub-ligase activity in mitochondrial quality control ([@B110]) appears more relevant to PD pathogenesis than in LB formation.

Since proteasomes can degrade α-syn ([@B11]), and regulation of α-syn ubiquitination has been implicated in PD ([@B74]; [@B115], [@B114]), enhancing UPS activity could stimulate α-syn degradation and reduce aggregation-linked pathology ([@B98]). Non-aggregated α-syn could be specifically targeted to the proteasome, thereby preventing aggregated α-syn from further inhibiting proteasome catalytic activity ([@B134]; [@B129]; [@B23]). Selective enhancement of α-syn targeting to proteasomes is a more desirable approach to broader enhancement of UPS activity, which may lead to serious adverse effects. This could be achieved by increasing the activity of the specific machinery that controls the ubiquitination of α-syn, such as the druggable deubiquitinase USP9X ([@B114], **Table [1](#T1){ref-type="table"}**), although only inhibitors have been reported so far ([@B105]). Deubiquitination of α-syn might redirect the α-syn burden toward the ALP, which is generally recognized as a more efficient α-syn degradation pathway than the UPS ([@B146]). It should be noted that α-syn ubiquitination can serve as a signal for lysosome-dependent degradation ([@B142]; [@B15]; [@B3]), illustrating a complex cross-talk between post-translational modifications of α-syn and cellular degradation machineries ([@B24]; [@B53]; [@B122]; [@B139]; [@B31]). It remains unclear which α-syn degradation pathway is favored, therefore further study is needed before a viable therapeutic strategy can be designed to enhance UPS-mediated α-syn degradation.

Autophagy-Lysosome Pathway
--------------------------

The ALP is thought to be the most efficient pathway for degradation of α-syn ([@B146]), with dysfunction causing accumulation and aggregation of α-syn. Defects in the ALP have been linked with an increasing number of genetic variants identified as causative or associated with PD risk ([@B47]), including Vps35, a component of the retromer that mediates retrograde transport from endosomes to Golgi, the lysosomal ATPase pump ATP13A2, and LRRK2 ([@B108]; [@B145]; [@B99]; [@B67]; [@B144]; [@B137]; [@B45]). Polymorphisms in genes encoding lysosomal enzymes, acid sphingomyelinase (*SMPD1* gene), and β-glucocerebrosidase (GBA, *GBA1* gene), are also risk factors for synucleinopathies ([@B94]; [@B29]; [@B47]). A reduction in GBA expression and activity is observed in the substantia nigra and cerebellum of patients with sporadic PD ([@B50]), and the inhibition of GBA or its transporter Limp2 is sufficient to stimulate α-syn aggregation through autophagic inhibition ([@B113]; [@B37]). Polymorphisms in the lysosomal K^+^ channel encoding gene *TMEM175* are risk factors for PD ([@B93]). TMEM175 deficiency causess ALP dysfunction and increased α-syn aggregation ([@B61]). Additional ALP-related genes were just recently linked to PD ([@B22]), converging into a unifying theory for PD pathogenesis, where the ALP is challenged by defects in synaptic exocytosis, endocytosis, and endosomal trafficking, resulting in neuron dysfunction and death ([@B143]).

Macroautophagy is responsible for degrading most of the aggregated, proteasome-resistant, α-syn, and enhancing this process represents a promising therapeutic strategy (**Figure [1](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). The mTOR inhibitor rapamycin activates macroautophagy, prevents α-syn accumulation and aggregation, and ameliorates motor symptoms, but adverse effects have been reported ([@B64]; [@B73]; [@B141]). More recently, it was shown that acetylation of α-syn increases macroautophagy-mediated degradation of α-syn aggregates, with knock-out of the α-syn deacetylase SIRT2 protects against α-syn--induced dopaminergic cell loss *in vivo* ([@B31], see **Table [1](#T1){ref-type="table"}**). Independent from UPS-targeting, modulation by the deubiquitinase USP8 and the Ub-ligase Nedd4 of α-syn modification by K63-linked Ub appears to control its autophagic degradation ([@B15]; [@B3]). A better understanding of the specific effects of various post-translational modifications will be necessary to appropriately modulate α-syn clearance by macroautophagy.

CMA specifically degrades physiologic α-syn (which contains a KFERQ-like motif, VKKDQ), whereas pathologic α-syn inhibits CMA, thus enhancing aggregation of itself and other LB components ([@B80]; [@B146]; [@B154]). Accordingly, overexpression of certain PD-associated microRNAs is suspected to be responsible for pathologic CMA downregulation through decreased Hsc70 and Lamp2A expression. This correlates with α-syn accumulation in brains of patients with PD ([@B4]; [@B91]). CMA-mediated degradation of α-syn and LRRK2 is also impaired by mutants of these proteins that cause inherited PD (A53T and A30P α-syn mutants; G2019S and R1441C LRRK2 mutants). These mutants are recognized by Hsc70 and targeted to the lysosomal membrane, but fail to be translocated into the lysosome due to an aberrantly high affinity for Lamp2A. This impairs CMA-mediated degradation of these proteins and CMA activity, contributing to PD pathology ([@B26]; [@B99]). Deficiencies in CMA (caused by *LRRK2* or *VPS35* PD-associated mutations for example, [@B99]; [@B137]; [@B57]) cause accumulation of α-syn, favoring the emergence of aberrant α-syn species that hinder the function of the Lamp2A receptor. Lamp2A overexpression efficiently prevents α-syn burden in cellular and animal models of PD and counteracts motor deficits (see **Table [1](#T1){ref-type="table"}**). Whether this strategy can reverse α-syn pathology in a clinical context, in a safe and effective way, still needs to be determined, especially since CMA cannot mediate the degradation of aggregated species. The role of CMA in PD pathogenesis has been reviewed recently ([@B117]), and will not be discussed further here. Notably, strategies aiming at activating both macroautophagy and CMA are also being explored ([@B46]; [@B70]), such as overexpression of the transcription factor NRF2, which protects against α-syn pathology and increases its turnover through unknown ALP-dependent mechanisms ([@B128]).

A prerequisite for efficient α-syn degradation by ALP is the adequate function and hydrolytic capacity of lysosomes. Improper activity of lysosomal hydrolases, due to mutations, sorting defects, or altered lysosomal homeostasis, has emerged as a critical step in the development of PD ([@B143]; [@B47]) and other synucleinopathies, particularly those associated with lysosomal storage disorders (Gaucher disease, Niemann-Pick disease; [@B28]; [@B100]; [@B101]). Stimulating lysosome biogenesis via activation of ALP transcriptional regulator TFEB improves autophagic α-syn clearance ([@B32]; [@B65]), and reduces α-syn toxicity in rats ([@B32]). Enhancing lysosomal hydrolase activity also improves α-syn degradation by the ALP, as shown for the α-syn-cleaving proteases cathepsins D, B and L ([@B87]; [@B72]; [@B84]) or GBA ([@B155]). Finally, rescue of lysosomal hydrolase misfolding by small molecule chaperones ([@B119]; [@B155]) or enhancement of endo-lysosomal trafficking of ALP components ([@B25]; [@B87]; [@B137]) are likely to mitigate α-syn pathology.

Other PQC Mechanisms
--------------------

Other PQC mechanisms exist that are less commonly referred to in the context of α-syn pathology. α-syn synthesis could be reduced in the first place to prevent its accumulation. Several microRNAs target α-syn mRNA to reduce its expression in cell culture and *in vivo* ([@B63]; [@B36]; [@B127]). The therapeutic potential of this mechanism remains to be evaluated, especially regarding potential adverse effects of a lack of functional α-syn on the dopamine system ([@B1]). Finally, unconventional secretion of misfolded proteins (misfolding-associated protein secretion, MAPS) was recently suggested to protect individual cells from misfolded proteins by delivering them to the extracellular space ([@B71]). In the context of a multicellular organism, however, this secretion might be harmful by contributing to the prion-like spreading of misfolded proteins including α-syn.

Concluding Remarks
==================

Extensive genetic and experimental evidence indicate that PQC deficiencies influence the development of synucleinopathies. Despite the potential of several experimental strategies targeting PQC to attenuate α-syn pathology, translation into therapy is still pending. Whether these approaches will be clinically effective, where synuclein pathology is pre-existant, remains unknown. No successful clinical trial has been reported for synucleinopathies, but targeting PQC bears great promise as such strategies have proven effective to treat diseases such as cystic fibrosis or cancer ([@B138]; [@B56]). Further functional characterization of genes associated with synucleinopathies, will provide important insights regarding the molecular mechanisms that can be targeted to enhance PQC function, boost α-syn degradation, and prevent its aggregation. For patients with familial synucleinopathies, the upcoming era of personalized medicine, including the use of patient-derived induced pluripotent-stem cells and genome-editing, might allow correction of patient-specific mutations or PQC impairments. However, in sporadic cases, where genetic contributions are unknown (the majority of PD cases), simultaneous enhancement of several components of PQC machinery will likely be necessary to stop the progression, or even reverse the course, of these devastating neurodegenerative diseases.
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